Fusion will help launch new drug for Parkinson’s

Healthcare specialist Fusion Communications has been appointed to provide the PR support for a new drug for the treatment of Parkinson’s disease.

Healthcare specialist Fusion Communications has been appointed to

provide the PR support for a new drug for the treatment of Parkinson’s

disease.



Fusion was appointed by Orion Pharma UK, which is promoting the drug

Comtess (known generically as entacapone) in conjunction with Novartis

Pharmaceuticals UK.



The account was awarded following a three-way competitive pitch, said

Fusion assistant director Rachel Terry. The agency will run a media

campaign targeting professional and lay audiences.



Comtess is used in conjunction with levadopa, one of the main treatments

for Parkinson’s disease, to reduce the required dosage and lessen side

effects. Approximately 120,000 people in the UK have been diagnosed with

Parkinson’s disease.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.